Physician profile
Danah Jacks
NPI 1548634181
$5,094.43
in general payments reported to CMS, 2019-2025
25 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $2,181 · 2023: $751 · 2024: $1,605 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Travel and Lodging: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.18 |
| Travel and Lodging | $768.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,638.66 | 2021-2023 | Proclaim |
| Si-Bone, INC. | $922.74 | 2021-2024 | |
| Medtronic, INC. | $714.81 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Inceptiv |
| Novocure INC. | $260.82 | 2023-2024 | Optune |
| Nevro Corp. | $160.45 | 2021-2024 | Senza |
| Orthofix Medical, INC. | $131.01 | 2024-2025 | Spinal-Stim |
| Boston Scientific Corporation | $126.66 | 2024 | |
| Integra Lifesciences Corporation | $126.34 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2024 | |
| Relievant Medsystems, INC. | $124.92 | 2023 | Intracept |
| Arbor Pharmaceuticals, INC. | $123.20 | 2021 | |
| Azurity Pharmaceuticals, INC. | $116.26 | 2022-2023 | Gliadel |
| Sanara Medtech INC. | $103.97 | 2023 | Celleraterx |
| Bioventus LLC | $84.61 | 2022-2025 | Bonescalpel & Sonicone (O.R.), Sonastar |
| Aesculap, INC. | $77.76 | 2021-2023 | Aesculap |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61.62 | 2022-2023 | |
| Arteriocyte Medical Systems, INC. | $34.81 | 2023 | Magellan |
| Theragen, INC. | $28.43 | 2021-2025 | Actastim-S |
| Zimmer Biomet Holdings, INC. | $27.55 | 2024 | Neuro Plating System, Htr-Pekk |
| Otsuka America Pharmaceutical, INC. | $25.83 | 2023 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $19.55 | 2021 | |
| Ucb, INC. | $17.90 | 2023 | Briviact |
| Biocomposites INC | $14.22 | 2025 | Stimulan |
| Stryker Corporation | $13.83 | 2021 | |
| Lilly USA, LLC | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danah Jacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.